摘要
目的:探讨程序性死亡受体-配体1(PD-L1)在晚期非小细胞肺癌中的表达及其预后价值。方法:收集70例非小细胞肺癌患者肿瘤组织,通过免疫组化检测肿瘤组织中PD-L1的表达。Kaplan-Meier生存曲线及多变量Cox回归模型分析PD-L1表达与患者预后的关系。结果:70例肺癌标本中有36例(51.4%)PD-L1高表达。肿瘤细胞PD-L1高表达的患者预后较差,无进展生存时间较短[14个月(95%CI:12.06~17.45)vs 20个月(95%CI:17.05~23.26),P=0.007]。结论:PD-L1在国内非小细胞肺癌中也呈高表达,同时其表达水平与非小细胞肺癌患者的预后密切相关,可能是非小细胞肺癌的独立预后指标。
Objective:To investigate the expression and the prognostic value of programmed cell death-ligand 1(PD-L1)protein in human non-small cell lung cancer(NSCLC).Methods:Tumor tissues from 70 lung cancer patients were analyzed in this study and PD-L1 expressions in tumor tissue were detected by immunohistochemistry.Kaplan-Meier survival curves and multivariate Cox regression model were employed to analyze relationship between the expression of PD-L1 and the prognosis of the patients.Results:The result showed that PD-L1 was highly expressed in 36(51.4%)of 70 lung cancer specimens.Patients with high PD-L1 expression in NSCLC had a poor prognosis with shorter progression free survival time[14 months(95%CI:12.06-17.45)vs.20 months(95%CI:17.05-23.26),P=0.007].Conclusion:This study suggests that PD-L1 expression correlates closely with prognosis of patients with NSCLC and it might be an independent prognostic marker for NSCLC.
作者
熊磊
刘小龙
徐杨
罗立国
李德闽
申翼
XIONG Lei;LIU Xiaolong;XU Yang;LUO Liguo;LI Demin;SHEN Yi(Department of Cardiothoracic Surgery,Nanjing General Hospital of PLA,Nanjing 210002,China)
出处
《现代医学》
2020年第9期1169-1173,共5页
Modern Medical Journal
基金
东部战区总医院院管课题(2017014)。
